What is the catalog number for Ticagrelor?

The catalog number for Ticagrelor is HY-10064.

What sizes are available for Ticagrelor?

Ticagrelor is available in the following size(s): 5 mg, 10 mg, 10 mM - 1 mL, 50 mg, 100 mg, 500 mg, 1 g.

How many pack sizes does Ticagrelor come in?

Ticagrelor is available in 7 different pack sizes.

Is Ticagrelor in stock?

Ticagrelor is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Ticagrelor?

Ticagrelor is manufactured by QuantiMol.

What is the estimated delivery time for Ticagrelor?

Estimated delivery time for Ticagrelor is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Ticagrelor?

The safety data sheet for Ticagrelor is available here: http://file.medchemexpress.com/batch_PDF/HY-10064/Ticagrelor-SDS-MedChemExpress.pdf.

Ticagrelor

Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.

Product Specifications

CAS Number

274693-27-5

Product Name Alternative

AZD6140; AR-C 126532XX

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

P2Y Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Ticagrelor.html

Purity

99.98

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O[C@H]1[C@@H](O)[C@H](N2N=NC3=C(N[C@H]4[C@H](C5=CC=C(F)C(F)=C5)C4)N=C(SCCC)N=C32)C[C@@H]1OCCO

Molecular Formula

C23H28F2N6O4S

Molecular Weight

522.57

Precautions

H302, H315, H319, H335

References & Citations

[1]Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128 (23) :2717-2728.|[2]Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136 (1) :234-40.|[3]Sugidachi A, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169 (1) :82-9.